EGFR and neoplasm: While the authors didn’t observe a significant correlation between tumor response and EGFR mutational status, the number of patients in this study was limited (22 patients with mutant and 8 patients with wt EGFR), and sorafenib was used as a single agent64, which does not correspond to the sorafenib-osimertinib combination we propose here.